Chemomab Therapeutics Ltd. American Depositary Share CMMB
$1.90
-1.04%
at last close
Analyst Consensus
- Consensus Rating
- Buy (1 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $25.00
- Implied Upside
- +1215.8%
- Price Target Range
- $25.00 – $25.00
- Analysts (12 mo)
- 1
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2025-08-27 | OppenheimerJeff Jones |
Maintains | Outperform | $10 → $25 |
| 2025-05-16 | OppenheimerJeff Jones |
Maintains | Outperform | $11 → $10 |
| 2025-02-20 | Maxim GroupMichael Okunewitch |
Maintains | Buy | $4 → $7 |
| 2024-11-15 | OppenheimerJeff Jones |
Reiterates | Outperform | $13 → $11 |
| 2024-05-13 | Maxim GroupMichael Okunewitch |
Initiates coverage on | Buy | $4 |
| 2024-05-06 | OppenheimerJeff Jones |
Upgrades | Perform → Outperform | $6 |
| 2024-03-08 | OppenheimerJeff Jones |
Maintains | Perform | — |
| 2023-12-19 | Roth MKMDylan Dupuis |
Reinstates | Buy | $7 |
| 2023-10-06 | Roth MKMDylan Dupuis |
Initiates coverage on | Buy | $7 |
| 2023-06-07 | OppenheimerJeff Jones |
Downgrades | Outperform → Perform | — |
| 2023-04-18 | OppenheimerJeff Jones |
Maintains | Outperform | $12 → $7 |
| 2022-03-10 | OppenheimerJeff Jones |
Maintains | Outperform | $30 → $20 |
| 2021-12-07 | Aegis CapitalNathan Weinstein |
Initiates coverage on | Buy | $30 |
| 2021-05-26 | Cantor FitzgeraldKristen Kluska |
Initiates coverage on | Overweight | $45 |
| 2021-05-07 | OppenheimerJeff Jones |
Initiates coverage on | Outperform | $42 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $1.90
- Market Cap
- $14.07 million
- 52-Week Range
- $1.35 – $4.92
- Average Volume
- 224K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.